Diagnostic yield of capsule endoscopy for small bowel arteriovenous malformations in patients with hereditary hemorrhagic telangiectasia: a systematic review and meta-analysis

Abstract

Background and study aims Small bowel arteriovenous malformations (AVMs) pose a bleeding risk and have traditionally been diagnosed by invasive enteroscopic procedures in patients with hereditary hemorrhagic telangiectasia (HHT). Capsule endoscopy (CE) is emerging as a safe and non-invasive alternative for small intestinal evaluation, but its diagnostic yield and utility in diagnosing small bowel AVMs in HHT patients are understudied. The aim of this study was to meta-analyze the utility of CE for diagnosing AVMs in HHT patients.

Methods A meta-analysis and systematic review of the literature on CE in HHT patients identified in the PubMed, EMBASE, Scopus, and Cochrane databases from inception to March 2018 were conducted. Summary effects were estimated using a random effects model.

Results After applying exclusion criteria, five studies (n = 124 patients) were eligible for meta-analysis. The pooled diagnostic yield for visualization of small bowel AVMs by CE was 77.0 % (95 % CI 65.8 – 85.4 %, P < 0.001).

Conclusions CE has a good diagnostic yield for small bowel AVMs in HHT. It can be regarded as a sufficient, noninvasive diagnostic modality for identifying small bowel AVMs in HHT patients.

• References

• 1 Garg N, Khunger M, Gupta A. et al. Optimal management of hereditary hemorrhagic telangiectasia. J Blood Med 2014; 5: 191-206
• 2 Kjeldsen AD, Kjeldsen J. Gastrointestinal bleeding in patients with hereditary hemorrhagic telangiectasia. Am J Gastroenterol 2000; 95: 415-418
• 3 Gerson LB, Fidler JL, Cave DR. et al. ACG Clinical Guideline: Diagnosis and Management of Small Bowel Bleeding. Am J Gastroenterol 2015; 110: 1265-1287 quiz 1288
• 4 Canzonieri C, Centenara L, Ornati F. et al. Endoscopic evaluation of gastrointestinal tract in patients with hereditary hemorrhagic telangiectasia and correlation with their genotypes. Genet Med 2014; 16: 3-10
• 5 Chamberlain SM, Patel J, Carter Balart J. et al. Evaluation of patients with hereditary hemorrhagic telangiectasia with video capsule endoscopy: a single-center prospective study. Endoscopy 2007; 39: 516-520
• 6 Greve E, Moussata D, Gaudin JL. et al. High diagnostic and clinical impact of small-bowel capsule endoscopy in patients with hereditary hemorrhagic telangiectasia with overt digestive bleeding and/or severe anemia. Gastrointest Endosc 2010; 71: 760-767
• 7 Ingrosso M, Sabba C, Pisani A. et al. Evidence of small-bowel involvement in hereditary hemorrhagic telangiectasia: a capsule-endoscopic study. Endoscopy 2004; 36: 1074-1079
• 8 van Tuyl SA, Letteboer TG, Rogge-Wolf C. et al. Assessment of intestinal vascular malformations in patients with hereditary hemorrhagic teleangiectasia and anemia. Eur J Gastroenterol Hepatol 2007; 19: 153-158
• 9 Cianci R, Urgesi R, Tortora A. et al. The role of capsule endoscopy and device assisted enteroscopy for small bowel lesions in hereditary hemorrhagic telangiectasia. Dig Liver Dis 2017; 25: pii: S1590-8658(17)30891-5
• 10 Westermann CJJ, Rosina AF, De Vries V. et al. The prevalence and manifestations of hereditary hemorrhagic telangiectasia in the Afro-Caribbean population of the Netherlands Antilles: A family screening. Am J Med Genet 2003; 116A: 324-328
• 11 Govani FS, Shovlin CL. Hereditary haemorrhagic telangiectasia: a clinical and scientific review. Eur J Hum Genet 2009; 17: 860-871
• 12 Johnson DW, Berg JN, Baldwin MA. et al. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 1996; 13: 189-195
• 13 McAllister KA, Grogg KM, Johnson DW. et al. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 1994; 8: 345-351
• 14 Faughnan ME, Palda VA, Garcia-Tsao G. et al. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet 2011; 48: 73-87
• 15 Plauchu H, de Chadarevian JP, Bideau A. et al. Age-related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population. Am J Med Genet 1989; 32: 291-297
• 16 Longacre AV, Gross CP, Gallitelli M. et al. Diagnosis and management of gastrointestinal bleeding in patients with hereditary hemorrhagic telangiectasia. Am J Gastroenterol 2003; 98: 59-65
• 17 Committee AT, Chauhan SS, Manfredi MA. et al. Enteroscopy. Gastrointest Endosc 2015; 82: 975-990
• 18 Mourad FH, Leong RW. Role of hemostatic powders in the management of lower gastrointestinal bleeding: A review. J Gastroenterol Hepatol 2018; 2018: 1-9
• 19 Nardone G, Compare D, Martino A. et al. Pharmacological treatment of gastrointestinal bleeding due to angiodysplasias: A position paper of the Italian Society of Gastroenterology (SIGE). Dig Liver Dis 2018; 50: 542-548
• 20 Sami SS, Al-Araji SA, Ragunath K. Review article: gastrointestinal angiodysplasia - pathogenesis, diagnosis and management. Aliment Pharmacol Ther 2014; 39: 15-34
• 21 Gunjan D, Sharma V, Rana SS. et al. Small bowel bleeding: a comprehensive review. Gastroenterol Rep (Oxf) 2014; 2: 262-275
• 22 Gostout CJ, Bowyer BA, Ahlquist DA. et al. Mucosal vascular malformations of the gastrointestinal tract: clinical observations and results of endoscopic neodymium: yttrium-aluminum-garnet laser therapy. Mayo Clin Proc 1988; 63: 993-1003
• 23 Sargeant IR, Loizou LA, Rampton D. et al. Laser ablation of upper gastrointestinal vascular ectasias: long term results. Gut 1993; 34: 470-475
• 24 Bown SG, Swain CP, Storey DW. et al. Endoscopic laser treatment of vascular anomalies of the upper gastrointestinal tract. Gut 1985; 26: 1338-1348
• 25 Szilagyi A, Ghali MP. Pharmacological therapy of vascular malformations of the gastrointestinal tract. Can J Gastroenterol 2006; 20: 171-178
• 26 American Society of Health-System Pharmacists. ed. AHFS Clinical Drug Information. 2018 Available at: http://www.ahfsdruginformation.com/ Accessed November 14, 2018
• 27 Koch HJ, Escher GC, Lewis JS. Hormonal management of hereditary hemorrhagic telangiectasia. J Am Med Assoc 1952; 149: 1376-1380
• 28 Jackson CS, Gerson LB. Management of gastrointestinal angiodysplastic lesions (GIADs): a systematic review and meta-analysis. Am J Gastroenterol 2014; 109: 474-483
• 29 Nardone G, Compare D, Martino A. et al. Pharmacological treatment of gastrointestinal bleeding due to angiodysplasias: A position paper of the Italian Society of Gastroenterology (SIGE). Dig Liver Dis 2018; 50: 542-548
• 30 Epperla N, Hocking W. Blessing for the bleeder: bevacizumab in hereditary hemorrhagic telangiectasia. Clin Med Res 2015; 13: 32-35
• 31 Sehl ME, MGruber T, McWilliams JP. et al. Successful management of chronic gastrointestinal hemorrhage using bevacizumab in the setting of hereditary hemorrhagic telangiectasia. Am J Hematol 2015; 90: 561-563
• 32 Kochanowski J, Sobieszczańska M, Tubek S. et al. Successful therapy with bevacizumab in a case of hereditary hemorrhagic telangiectasia. Hum Vaccin Immunother 2015; 11: 680-681
• 33 Bennesser AlaouiH, Lehraiki M, Hamaz S. et al. Bevacizumab: a new success in hereditary hemorrhagic telangiectasia. Rev Med Internet 2015; 36: 623-625
• 34 Wee JW, Jeon YW, Eun JY. et al. Hereditary hemorrhagic telangiectasia treated with low dose intravenous bevacizumab. Blood Res 2014; 49: 192-195
• 35 Epperla N, Kapke JT, Karafin M. et al. Effect of systemic bevacizumab in severe hereditary hemorrhagic telangiectasia associated with bleeding. Am J Hematol 2016; 91: E313-314
• 36 Ou G, Galorport C, Enns R. Bevacizumab and gastrointestinal bleeding in hereditary hemorrhagic telangiectasia. World J Gastrointest Surg 2016; 8: 792-795
• 37 Bertoli LF, Lee PL, Lallone L. et al. Intravenous bevacizumab therapy in a patient with hereditary hemorrhagic telangiectasia, ENG E137K, alcoholic cirrhosis, and portal hypertension. Case Rep Gastroenterol 2017; 11: 293-304
• 38 Guilhem A, Fargeton AE, Simon AC. et al. Intravenous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): A retrospective study of 46 patients. PLoS One 2017; 12: 1-12
• 39 Bernardes C, Santos S, Loureiro R. et al. Bevacizumab for refractory gastrointestinal bleeding in Rendu-Osler-Weber disease. GE Port J Gastroenterol 2018; 25: 91-95
• 40 Al-Samkari H, Kritharis A, Rodriguez-Lopez JM. et al. systemic bevacizumab for the treatment of chronic bleeding in hereditary hemorrhagic telangiectasia. J Intern Med 2018; 1: 1-19
• 41 Iyer VN, Apala DR, Pannu BS. et al. Intravenous bevacizumab for refractory hereditary hemorrhagic telangiectasia-related epistaxis and gastrointestinal bleeding. Mayo Clin Proc 2018; 93: 155-166
• 42 Kanellopoulou T, Alexopoulou A. Bevacizumab in the treatment of hereditary hemorrhagic telangiectasia. Expert Opin Biol Ther 2013; 13: 1315-1323
• 43 Lupu A, Stefanescu C, Treton X. et al. Bevacizumab as rescue treatment for severe recurrent gastrointestinal bleeding in hereditary hemorrhagic telangiectasia. J Clin Gastroenterol 2013; 47: 256-257
• 44 Lazaraki G, Akriviadis E, Pilpilidis I. et al. Low dose of bevacizumab is safe and effective in preventing bleeding episodes in hereditary hemorrhagic telangiectasia. Am J Gastroenterol 2011; 106: 2204-2206
• 45 Bowcock SJ, Patrick HE. Lenalidomide to control gastrointestinal bleeding in hereditary haemorrhagic telangiectasia: potential implications for angiodysplasias?. Br J Haematol 2009; 146: 220-222
• 46 Haq AU, Glass J, Netchvolodoff CV. et al. Hereditary hemorrhagic telangiectasia and danazol. Ann Intern Med 1988; 109: 171
• 47 Massoud OI, Youssef WI, Mullen KD. Resolution of hereditary hemorrhagic telangiectasia and anemia with prolonged alpha-interferon therapy for chronic hepatitis C. J Clin Gastroenterol 2004; 38: 377-379
• 48 Skaro AI, Marotta PJ, McAlister VC. Regression of cutaneous and gastrointestinal telangiectasia with sirolimus and aspirin in a patient with hereditary hemorrhagic telangiectasia. Ann Intern Med 2006; 144: 226-227
• 49 Park JJ, Cheon JH, Kim HM. et al. Negative capsule endoscopy without subsequent enteroscopy does not predict lower long-term rebleeding rates in patients with obscure GI bleeding. Gastrointest Endosc 2010; 71: 990-997
• 50 Kim JB, Ye BD, Song Y. et al. Frequency of rebleeding events in obscure gastrointestinal bleeding with negative capsule endoscopy. J Gastroenterol Hepatol 2013; 28: 834-840
• 51 Pongprasobchai S, Chitsaeng S, Tanwandee T. et al. Yield, etiologies and outcomes of capsule endoscopy in Thai patients with obscure gastrointestinal bleeding. World J Gastrointest Endosc 2013; 5: 122-127
• 52 Min YW, Kim JS, Jeon SW. et al. Long-term outcome of capsule endoscopy in obscure gastrointestinal bleeding: a nationwide analysis. Endoscopy 2014; 46: 59-65
• 53 Saurin JC, Delvaux M, Vahedi K. et al. Clinical impact of capsule endoscopy compared to push enteroscopy: 1-year follow-up study. Endoscopy 2005; 37: 318-323
• 54 Hindryckx P, Botelberge T, De Vos M. et al. Clinical impact of capsule endoscopy on further strategy and long-term clinical outcome in patients with obscure bleeding. Gastrointest Endosc 2008; 68: 98-104
• 55 Leighton JA, Sharma VK, Hentz JG. et al. Capsule endoscopy versus push enteroscopy for evaluation of obscure gastrointestinal bleeding with 1-year outcomes. Dig Dis Sci 2006; 51: 891-899
• 56 Strate LL, Gralnek IM. ACG Clinical Guideline: Management of patients with acute lower gastrointestinal bleeding. Am J Gastroenterol 2016; 111: 755
• 57 Gralnek IM, Dumonceau JM, Kuipers EJ. et al. Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2015; 47: a1-46